PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954638
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1954638
The global extracorporeal membrane oxygenation (ECMO) machine market was valued at USD 552.8 million in 2025 and is projected to grow to USD 574.8 million in 2026. The market is further expected to reach USD 790.05 million by 2034, exhibiting a CAGR of 4.06% during the forecast period (2026-2034).
North America dominated the global ECMO machine market with a 49.36% market share in 2025, driven by the high prevalence of cardiovascular diseases, rising number of surgical procedures, and strong presence of leading market players.
ECMO is an advanced life-support system used to oxygenate blood outside the body and provide circulatory support. It operates primarily in two modes: Veno-Arterial (VA) and Veno-Venous (VV). The technology is widely used in patients suffering from respiratory failure, acute respiratory distress syndrome (ARDS), pulmonary embolism, cardiogenic shock, open-heart surgery complications, and severe COVID-19 cases.
Market Drivers
Rising Prevalence of Cardiovascular and Respiratory Diseases
The growing burden of cardiovascular diseases (CVDs) and respiratory disorders is a major factor driving ECMO machine demand. Globally, cardiovascular diseases account for approximately 18.6 million deaths annually. Additionally, ARDS, chronic obstructive pulmonary disease (COPD), and respiratory failure cases continue to rise, increasing the need for advanced life-support systems.
In the U.S., around 190,000 ARDS cases are reported annually. Furthermore, nearly 4,600 lung transplant procedures are performed globally each year, with North America and Europe accounting for nearly 80% of the total. These factors significantly contribute to the expansion of the ECMO machine market.
Technological Advancements
Continuous innovations such as miniaturized oxygenators, advanced rotary pumps, dual-lumen cannula, improved circuit coatings, and magnetic levitation centrifugal pumps have enhanced patient outcomes. Modern ECMO systems offer rapid priming, lower blood flow resistance, reduced plasma leakage, and minimized complications, encouraging higher adoption across hospitals and critical care units.
COVID-19 Impact
The COVID-19 pandemic positively impacted the ECMO machine market due to increased demand for respiratory and circulatory support. Hospitals expanded ECMO capacity to treat critically ill COVID-19 patients. Major players reported revenue growth during the pandemic due to increased demand for ECMO systems.
The surge in usage during 2020 and 2021 strengthened the adoption of ECMO machines globally and established them as critical infrastructure in intensive care units.
Market Restraints
Despite strong demand, the high cost of ECMO systems limits adoption in developing economies. In the U.S., an ECMO system costs between USD 152,000 and USD 170,000, while in India, prices range from USD 35,000 to USD 48,000. The total procedural cost, including consumables and skilled personnel, further increases affordability challenges, especially in low-income healthcare systems.
By Type
The market is segmented into Veno-Arterial (VA) and Veno-Venous (VV) systems.
By Application
The market is segmented into adult, pediatric, and neonatal.
North America
North America led the market in 2025, supported by advanced healthcare infrastructure and strong manufacturer presence. The U.S. continues to drive regional growth due to high cardiovascular mortality rates.
Europe
Europe is expected to grow at a substantial rate through 2034 due to favorable reimbursement policies and increased R&D investments.
Asia Pacific
Asia Pacific is projected to witness the highest CAGR during 2026-2034, supported by expanding ECMO centers, large patient pool, and growing healthcare investments in China, Japan, and India.
Latin America & Middle East & Africa
These regions are expected to grow at a moderate pace due to improving healthcare infrastructure and increasing adoption of advanced medical technologies.
Competitive Landscape
The ECMO machine market is consolidated, with major players including Getinge AB, Terumo Corporation, Medtronic plc, LivaNova PLC, Xenios AG, EUROSETS, ABIOMED, NIPRO, and Spectrum Medical.
Companies focus on product innovation, acquisitions, and regulatory approvals to strengthen their market position. Strategic developments and expansion of product portfolios are key competitive strategies.
Conclusion
The global ECMO machine market is set to grow steadily from USD 552.8 million in 2025 to USD 574.8 million in 2026, reaching USD 790.05 million by 2034, at a CAGR of 4.06%. Growth is primarily driven by the rising prevalence of cardiovascular and respiratory diseases, increasing adoption of advanced life-support technologies, and expanding ECMO centers worldwide.
North America remains the dominant region with a 49.36% share in 2025, while Asia Pacific is expected to register the fastest growth during the forecast period. Although high system costs pose a challenge, continuous technological advancements and growing healthcare investments are expected to sustain long-term market expansion through 2034.
Segmentation By Type, Application, and Region
By Type * Veno-Arterial
By Application
Adult
By Region * North America (By Type, By Application, By Country)